VTRS
Viatris Inc
+0.21 (+1.23%)17.23USD2.4M成交股數19.8B市值–本益比(近四季)1.4股價營收比+5.0%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 3.7B+5% | 3.5B+8% | 3.7B-1% | 3.7B-1% | 3.6B-2% | 3.2B-15% | 3.7B-5% | 3.8B-3% | 3.7B | 3.8B | 3.9B | 3.9B |
| 營業成本 | 2.3B | 2.4B | 2.6B | 2.4B | 2.2B | 2.1B | 2.3B | 2.4B | 2.2B | 2.2B | 2.3B | 2.3B |
| 毛利 | 1.5B+9% | 1.2B-0% | 1.1B-21% | 1.4B-5% | 1.3B-11% | 1.2B-27% | 1.5B-14% | 1.4B-10% | 1.5B | 1.6B | 1.7B | 1.6B |
| 毛利率 | 38.9% | 33.0% | 31.1% | 36.6% | 37.3% | 35.8% | 39.0% | 38.2% | 41.2% | 41.7% | 43.0% | 41.1% |
| 研發費用 | 248M | 249M | 275M | 250M | 219M | 222M | 198M | 204M | 200M | 203M | 211M | 208M |
| 銷售管理費用 | 1.1B | 929M | 1.0B | 887M | 929M | 948M | 1.0B | 1.0B | 1.0B | 1.0B | 1.1B | 1.0B |
| 營業利益 | 6.3M-97% | −79.7M-97% | −193M-185% | 179M-175% | 233M+14% | −2.9B+534% | 226M-50% | −240M-165% | 204M | −455M | 452M | 369M |
| 營業利益率 | 0.2% | -2.3% | -5.2% | 4.8% | 6.5% | -88.9% | 6.0% | -6.3% | 5.6% | -11.9% | 11.5% | 9.4% |
| 稅後淨利 | −119M+2483% | 176M-106% | −340M-459% | −128M-61% | −4.6M-104% | −3.0B+297% | 94.8M-71% | −326M-224% | 114M | −766M | 332M | 264M |
| 淨利率 | -3.2% | 5.0% | -9.2% | -3.4% | -0.1% | -93.8% | 2.5% | -8.6% | 3.1% | -20.0% | 8.4% | 6.8% |
| 稀釋 EPS | -0.10 | 0.15-106% | -0.34-525% | -0.11-59% | 0.00-100% | -2.55+305% | 0.08-70% | -0.27-223% | 0.09 | -0.63 | 0.27 | 0.22 |
| 稀釋股數 | 1.16B | 1.18B | – | 1.16B | 1.17B | 1.19B | 1.20B | 1.19B | 1.21B | 1.21B | 1.21B | 1.20B |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 887M | 1.8B | 1.3B | 975M | 566M | 755M | 1.9B | 917M | 1.0B | 992M | 1.3B | 629M |
| 應收帳款 | 3.1B | 3.1B | 3.0B | 3.4B | 3.3B | 3.1B | 3.7B | 3.6B | 3.6B | 3.7B | 3.7B | 3.6B |
| 存貨 | 3.9B | 3.9B | 4.0B | 4.1B | 4.3B | 4.1B | 4.1B | 3.9B | 3.8B | 3.5B | 3.7B | 3.6B |
| 總資產 | 35.0B | 36.8B | 37.2B | 37.9B | 38.4B | 38.5B | 44.8B | 45.3B | 47.3B | 47.7B | 48.7B | 48.7B |
| 有息負債 | 11.6B | 12.4B | 12.5B | 12.5B | 12.8B | 14.2B | 14.3B | 14.7B | 16.1B | 16.2B | 17.1B | 17.2B |
| 總負債 | 20.8B | 22.2B | 22.5B | 22.7B | 22.8B | 22.8B | 25.0B | 25.8B | 27.3B | 27.2B | 27.9B | 27.9B |
| 股東權益 | 14.3B | 14.7B | 14.7B | 15.2B | 15.6B | 15.7B | 19.8B | 19.5B | 20.0B | 20.5B | 20.9B | 20.8B |
| 負債比 | 59.3% | 60.2% | 60.4% | 59.9% | 59.5% | 59.3% | 55.8% | 56.9% | 57.7% | 57.1% | 57.2% | 57.2% |
| 淨現金(現金 − 有息負債) | −10.7B | −10.6B | −11.2B | −11.5B | −12.2B | −13.4B | −12.4B | −13.8B | −15.1B | −15.2B | −15.8B | −16.6B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 388M-27% | – | – | – | 536M | – | – | 615M | – | – | – |
| 資本支出 | – | 39.9M | – | – | – | 42.6M | – | – | 49.8M | – | – | – |
| 自由現金流 | – | 348M-29% | – | – | – | 493M | – | – | 565M | – | – | – |
| 折舊攤銷 | – | 676M | – | – | – | 665M | – | – | 691M | – | – | – |
| 買回庫藏股 | – | 0 | 82.2M | 67.9M | 175M | 175M | – | – | 250M | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 9.9% | – | – | – | 15.2% | – | – | 15.5% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 14.3B
| Developed Markets | 8.5B | 59.7% | -4.7% |
|---|---|---|---|
| Greater China | 2.3B | 16.4% | +7.7% |
| Emerging Markets | 2.2B | 15.5% | -1.8% |
| Japan Australia And New Zealand | 1.2B | 8.4% | -11.3% |
地區2025 年度 · 5.1B
| 美國 | 3.0B | 59.1% | -12.5% |
|---|---|---|---|
| 中國 | 2.1B | 40.9% | +8.8% |
產品／服務2025 年度 · 15.7B
| Brands | 9.2B | 58.6% | -0.2% |
|---|---|---|---|
| Generics | 5.1B | 32.3% | -7.8% |
| Creon | 366M | 2.3% | +11.5% |
| Celebrex | 273M | 1.7% | -4.4% |
| Yupelri | 267M | 1.7% | +11.9% |
| Effexor | 258M | 1.6% | +1.9% |
| Zoloft | 255M | 1.6% | +8.1% |
| Lipitor 小計 | 1.5B | 9.9% | +5.5% |
| Norvasc 小計 | 710M | 4.5% | +5.4% |
| Lyrica 小計 | 487M | 3.1% | -1.7% |
| Epi Pen Auto Injectors 小計 | 470M | 3.0% | +19.8% |
| Viagra 小計 | 408M | 2.6% | +3.2% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 14.3B | -3.0% | −3.5B | -24.7% | -3.00 | 1.9B |
| FY2024 | 14.7B | -4.5% | −634M | -4.3% | -0.53 | 2.0B |
| FY2023 | 15.4B | -5.1% | 54.7M | 0.4% | 0.05 | 2.5B |
| FY2022 | 16.2B | -9.0% | 2.1B | 12.8% | 1.71 | 2.6B |
| FY2021 | 17.8B | +50.7% | −1.3B | -7.1% | -1.05 | 2.6B |
| FY2020 | 11.8B | +4.0% | −670M | -5.7% | -1.11 | 989M |
| FY2019 | 11.4B | +0.9% | 0 | 0.0% | 0.03 | 1.6B |
| FY2018 | 11.3B | – | 353M | 3.1% | 0.68 | 2.1B |